ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,431.60
      -0.04%
      US Tech 100
      19,166.40
      0.51%
      Dow Jones
      38,589.16
      -0.15%
      Brent Oil
      82.275
      0.00%
      Bitcoin
      66,190.88
      0.28%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. PHAXIAM Therapeutics SA (PHXM)

      7. PHAXIAM Therapeutics SA (PHXM) News

      PHXM

      PHAXIAM Therapeutics (PHXM)

      PHAXIAM Therapeutics SA
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:PHXM
      DateTimeSourceHeadlineSymbolCompany
      03/11/20248:31AMEdgar (US Regulatory)Form 15F-12B - Securities registration termination of foreign private issuers [Section 12(b)]NASDAQ:PHXMPHAXIAM Therapeutics SA
      03/11/20242:00AMGlobeNewswire Inc.PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketNASDAQ:PHXMPHAXIAM Therapeutics SA
      03/06/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PHXMPHAXIAM Therapeutics SA
      03/04/20244:28PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
      03/04/20244:27PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
      03/04/20244:25PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
      03/04/20244:22PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
      03/04/20244:14PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
      03/04/20244:09PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PHXMPHAXIAM Therapeutics SA
      02/21/20246:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
      02/20/20244:05PMGlobeNewswire Inc.PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketNASDAQ:PHXMPHAXIAM Therapeutics SA
      01/19/202410:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
      01/18/20244:05PMGlobeNewswire Inc.PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024NASDAQ:PHXMPHAXIAM Therapeutics SA
      11/16/20237:41AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
      11/14/20234:05PMGlobeNewswire Inc.PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023NASDAQ:PHXMPHAXIAM Therapeutics SA
      10/25/20239:21AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
      10/24/20234:05PMGlobeNewswire Inc.PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureusNASDAQ:PHXMPHAXIAM Therapeutics SA
      10/23/20234:05PMGlobeNewswire Inc.TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendationNASDAQ:PHXMPHAXIAM Therapeutics SA
      10/11/20236:53AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
      10/05/20237:32AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
      09/26/20233:01PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
      09/21/20238:42AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
      09/18/20238:16AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
      09/15/20238:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
      09/07/20239:33AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
      07/27/20234:21PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
       Showing the most relevant articles for your search:NASDAQ:PHXM